Laman UtamaAAVXF • OTCMKTS
add
Abivax SA
Tutup sebelumnya
$5.81
Julat tahun
$5.81 - $11.05
Permodalan pasaran
396.37J EUR
Bilangan Purata
3.00
Nisbah P/E
-
Hasil dividen
-
Pertukaran utama
EPA
Berita pasaran
Kewangan
Penyata Pendapatan
Hasil
Pendapatan bersih
| (EUR) | Dis 2024info | Perubahan T/T |
|---|---|---|
Hasil | 2.00J | 72.23% |
Perbelanjaan pengendalian | 48.50J | 4.95% |
Pendapatan bersih | -47.30J | 1.24% |
Margin untung bersih | -2.36K | 42.65% |
Pendapatan bagi setiap syer | — | — |
EBITDA | -46.03J | -2.90% |
Kadar cukai berkesan | — | — |
Kunci Kira-kira
Jumlah aset
Jumlah liabiliti
| (EUR) | Dis 2024info | Perubahan T/T |
|---|---|---|
Pelaburan tunai dan jangka pendek | 144.36J | -44.72% |
Jumlah aset | 205.23J | -37.25% |
Jumlah liabiliti | 164.64J | 25.63% |
Jumlah ekuiti | 40.58J | — |
Syer tertunggak | 63.38J | — |
Harga kepada buku | 9.08 | — |
Pulangan pada aset | -56.64% | — |
Pulangan pada modal | -77.59% | — |
Aliran Tunai
Perubahan bersih dalam tunai
| (EUR) | Dis 2024info | Perubahan T/T |
|---|---|---|
Pendapatan bersih | -47.30J | 1.24% |
Tunai daripada operasi | -34.45J | 0.91% |
Tunai daripada pelaburan | 1.15J | 136.10% |
Tunai daripada pembiayaan | -6.06J | -105.54% |
Perubahan bersih dalam tunai | -39.05J | -156.77% |
Aliran tunai bebas | -26.53J | -4.57% |
Perihal
Abivax SA is a clinical stage biotechnology company focused on developing innovative treatments that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases.
Abivax has one program in clinical development with its lead drug candidate, obefazimod, to treat ulcerative colitis. Another program in Crohn’s disease is also in preparation and other potential inflammatory indications are being evaluated.
The company’s headquarters are based in Paris, France with a US office in Waltham, MA. Abivax’s R&D work is conducted at its research center based in Montpellier, France. Wikipedia
Diasaskan
4 Dis 2013
Tapak web
Pekerja
69
